Drug Target Review

APRIL 7, 2025

GPCRs are critical targets for drug development due to their involvement in numerous disease pathologies, with many medications working by either activating or inhibiting these receptors. 2022) Why 90% of clinical drug development fails and how to improve it?, References Sun D, et al. doi:10.1016/j.apsb.2022.02.002.

Fragment Screening 52

Fragment Screening Drugs Small Molecule Biophysical Assays 52

Sygnature Discovery

JANUARY 17, 2023

Sygnature Discovery’s acquisition of SB Drug Discovery This transaction will offer a strategic advantage for both companies, to enable further expansion of the businesses and their capabilities, and forms part of Sygnature’s strategic plan to continuously invest in the expansion of its leading integrated drug discovery solutions.

Compound Screening 52

Compound Screening Marketing Assay Development Drugs 52

Drug Target Review

OCTOBER 3, 2024

In 2024 alone, almost 50 antibody drug candidates are anticipated to enter regulatory review, the majority of which are mAbs. Aside from the advent of complex antibody-based drugs, the industry is facing some additional changes which are shaping drug development. Adapted from Harth S et al. (8) 8) under a CC BY-NC-ND 4.0.

Molecular Biology 52

Molecular Biology Pharmacokinetics Laboratories Animal Testing 52

Agency IQ

FEBRUARY 2, 2024

The EMA started providing guidance on the clinical development of anticancer therapeutics in 1996. The document has been updated over time to implement advances in understanding cancer and drug development. In 2005, the guidance was updated to include non-cytotoxic drugs were gaining in importance. medical practice.

Clinical Trials 40

Clinical Trials Trials Treatment Disease 40